↓ Skip to main content

ONE SHOT - single shot radiotherapy for localized prostate cancer: study protocol of a single arm, multicenter phase I/II trial

Overview of attention for article published in Radiation Oncology, September 2018
Altmetric Badge

About this Attention Score

  • Above-average Attention Score compared to outputs of the same age (59th percentile)

Mentioned by

twitter
6 tweeters

Citations

dimensions_citation
10 Dimensions

Readers on

mendeley
31 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
ONE SHOT - single shot radiotherapy for localized prostate cancer: study protocol of a single arm, multicenter phase I/II trial
Published in
Radiation Oncology, September 2018
DOI 10.1186/s13014-018-1112-0
Pubmed ID
Authors

Thomas Zilli, Marta Scorsetti, Daniel Zwahlen, Ciro Franzese, Robert Förster, Niccolò Giaj-Levra, Nikolaos Koutsouvelis, Aurelie Bertaut, Michel Zimmermann, Giuseppe Roberto D’Agostino, Filippo Alongi, Matthias Guckenberger, Raymond Miralbell

Abstract

Stereotactic body radiotherapy (SBRT) is an emerging treatment alternative for patients with localized prostate cancer. Promising results in terms of disease control and toxicity have been reported with 4 to 5 SBRT fractions. However, question of how far can the number of fractions with SBRT be reduced is a challenging research matter. As already explored by some authors in the context of brachytherapy, monotherapy appears to be feasible with an acceptable toxicity profile and a promising outcome. The aim of this multicenter phase I/II prospective trialis to demonstrate early evidence of safety and efficacy of a single-fraction SBRT approach for the treatment of localized disease. Patients with low- and intermediate-risk localized prostate cancer without significant tumor in the transitional zone will be treated with a single SBRT fraction of 19 Gy to the whole prostate gland with urethra-sparing (17 Gy). Intrafractional motion will be monitored with intraprostatic electromagnetic transponders. The primary endpoint of the phase I part of the study will be safety as assessed by CTCAE 4.03 grading scale, while biochemical relapse-free survival will be the endpoint for the phase II. The secondary endpoints include acute and late toxicity, quality of life, progression-free survival, and prostate-cancer specific survival. This is the first multicenter phase I/II trial assessing the efficacy and safety of a single-dose SBRT treatment for patients with localized prostate cancer. If positive, results of ONE SHOT may help to design subsequent phase III trials exploring the role of SBRT monotherapy in the exclusive radiotherapy treatment of localized disease. Clinicaltrials.gov identifier: NCT03294889 ; Registered 27 September 2017.

Twitter Demographics

The data shown below were collected from the profiles of 6 tweeters who shared this research output. Click here to find out more about how the information was compiled.

Mendeley readers

The data shown below were compiled from readership statistics for 31 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Unknown 31 100%

Demographic breakdown

Readers by professional status Count As %
Other 5 16%
Student > Doctoral Student 4 13%
Student > Master 3 10%
Researcher 2 6%
Professor > Associate Professor 2 6%
Other 5 16%
Unknown 10 32%
Readers by discipline Count As %
Medicine and Dentistry 16 52%
Computer Science 1 3%
Nursing and Health Professions 1 3%
Physics and Astronomy 1 3%
Energy 1 3%
Other 1 3%
Unknown 10 32%

Attention Score in Context

This research output has an Altmetric Attention Score of 3. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 23 September 2019.
All research outputs
#5,018,413
of 15,899,905 outputs
Outputs from Radiation Oncology
#293
of 1,616 outputs
Outputs of similar age
#107,472
of 276,616 outputs
Outputs of similar age from Radiation Oncology
#1
of 1 outputs
Altmetric has tracked 15,899,905 research outputs across all sources so far. This one is in the 48th percentile – i.e., 48% of other outputs scored the same or lower than it.
So far Altmetric has tracked 1,616 research outputs from this source. They receive a mean Attention Score of 2.4. This one has done well, scoring higher than 79% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 276,616 tracked outputs that were published within six weeks on either side of this one in any source. This one has gotten more attention than average, scoring higher than 59% of its contemporaries.
We're also able to compare this research output to 1 others from the same source and published within six weeks on either side of this one. This one has scored higher than all of them